Abstract
A newly developed continuous glucose monitor (CGM) incorporates a non-thrombogenic blood withdrawal system and a glucose electrode which generates a continuous tracing of real blood glucose (BG) during an Arginine-Insulin GH Stimulation Test (AIST) which was administered to seven children with short stature. The intravenous infusion of arginine was associated with an increase of BG from a baseline of 83 ± 10.9 to 107.7 ± 14.9 (mg/100 ml ± 1 SD). The peak level was reached 26.3 ± 6.5 minutes, and returned to baseline 51.3 ± 9.5 minutes, after the IV injection. The nadir in BG occurred 30.4 ± 8.5 minutes after IV insulin. The baseline level of 76.6 ± 10.1 mg/100 ml ± 1 SD fell to 29.1±6.2. The BG returned to normal 57.2 ± 7.5 minutes after the IV injection. Symptoms of hypoglycemia may force premature termination of the AIST. In two of the patients the AIST was continued despite symptoms because the BG level was increasing at the time. The use of CGM increases the safety of the AIST by providing real time level of BG.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
